Compare IDEXX Laboratories, Inc. (IDXX) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Matson Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Matson Inc trades at $225.67 (market cap $6.81B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.9× Matson Inc's market cap, and Matson Inc pays a 0.67% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Matson Inc for 23 Days on average.
| IDXX | MATX | |
|---|---|---|
Market Cap | $40.43B | $6.81B |
Volume | 692,164 | 255,080 |
Sector | Health | Industrials |
52-Week High | $766.68 | $238.60 |
52-Week Low | $504.70 | $88.05 |
Typical Hold Time | 46 Days | 23 Days |
Enterprise Value | $41.32B | $7.41B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Matson (MATX) trades at $227.79, up 2.18% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with 13.41% net income margin and 17.21% ROE, supported by positive analyst sentiment (66.7% buy ratings). Recent Q2 2026 earnings of $4.27 per share exceeded expectations by 12.7%, with the company raising full-year guidance amid resilient consumer demand and stable Trans-Pacific trade conditions.
Outlook remains positive with projected revenue growth to $3.5B in 2026 and improved cash flow. Key risks include freight market volatility and competitive pressures. Wall Street sees 27.3% upside potential based on average price targets, while institutional buying activity from Bank of America and Deutsche Bank signals confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
